61 Results for "

BCMA

" in MedChemExpress (MCE) Product Catalog:
Products (61)

61 Results for "BCMA" in MCE Product Catalog:

8
8 Publications Verification
Cat. No.: HY-15578
CAS No.: 863971-19-1
Purity:  99.96%
Synonyms: Maleimidocaproyl monomethylauristatin F
Research Areas:  

Cancer

McMMAF (Maleimidocaproyl monomethylauristatin F) is an active molecule linker for ADC, made by coupling the powerful microtubule inhibitor Monomethyl auristatin F (MMAF) (HY-15579) with the protecting group maleimidocaproyl. McMMAF can be conjugated with anti-BCMA antibodies to form J6M0-mcMMAF, promoting apoptosis and inhibiting tumor growth .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-P9980
CAS No.: 2061894-48-0
Synonyms: GSK2857914

Research Areas:  

Cancer

Belantamab (GSK2857916) is a humanized IgG1 anti-BCMA/TNFRSF17 monoclonal antibody. Belantamab is linked to MMAF (HY-15579) through a non-cleavable ADC linker to synthesize the antibody-active molecule conjugate (ADC) Belantamab mafodotin (HY-P3239). After binding to BCMA on the surface of tumor cells, Belantamab mafodotin enters the cell through receptor-mediated endocytosis. After entering the cell, Belantamab mafodotin releases MMAF, blocks cell division by inhibiting tubulin polymerization, arrests the cell cycle and induces cell apoptosis. Belantamab can be used for the study of multiple myeloma, especially relapsed/refractory multiple myeloma .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P3239
CAS No.: 2050232-20-5
Synonyms: GSK2857916; Belantamab mafodotin-blm
Research Areas:  

Cancer

Belantamab mafodotin (GSK2857916) is composed of humanized and focused monoclonal antibody against B cell maturation antigen (BCMA) and McMMAF. The antibody portion is Belantamab (HY-P9980), and the drug-linker conjugate for ADC is McMMAF (HY-15578). Belantamab mafodotin has anti-myeloma activity .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P99814
CAS No.: 2250292-39-6
Synonyms: AMG-701

Target:  

CD3

Research Areas:  

Inflammation/Immunology Cancer

Pavurutamab (AMG-701) is a bispecific T cell engager molecule that anti-CD3 and anti-B cell maturation antigens (BCMA). Pavurutamab has an extended half-life based on Pacanalotamab (HY-P99798). The Fc of Pavurutamab is coupled to molecules to improve pharmacokinetic parameters. Pavurutamab has potential applications in immune regulation and multiple myeloma (MM) .
loading...
    loading...
Cat. No.: HY-P99392
CAS No.: 2119595-80-9
Synonyms: JNJ-7957; JNJ-64007957; Tecvayli

Target:  

CD3

Research Areas:  

Cancer

Teclistamab is a human bispecific antibody to BCMA and CD3 that recognizes BCMA on target cells and CD3 on T cells and induces T cell-mediated cytotoxicity leading to T cell activation and subsequent target cell lysis. Teclistamab can be used in studies of diseases related to multiple myeloma (MM) .
loading...
    loading...
Cat. No.: HY-P991155
CAS No.: 2988886-91-3
Synonyms: JNJ-79635322; JNJ-5322

Target:  

CD3 TNF Receptor

Research Areas:  

Cancer

Ramantamig (JNJ-79635322) is a humanized monoclonal antibody targeting human CD3ε, GPRC5D, and TNFRSF17 (BCMA). Ramantamig binds to BCMA and GPRC5D on multiple myeloma cells, binds to CD3ε on T cells, forms immunological synapses, and enables T-cell-mediated cytotoxicity. Ramantamig activates T cells concomitantly with inducing myeloma cell cytotoxicity, with no nonspecific T-cell activation in the absence of target myeloma cells. Ramantamig carries mutations to reduce interaction with Fc receptors and disrupt protein A binding of monomeric and homodimerized chains. Ramantamig can be used for the research of multiple myeloma .
loading...
    loading...
Cat. No.: HY-P990980
CAS No.: 2919209-65-5
Synonyms: CND-106; EMB-06

Target:  

CD3

Research Areas:  

Inflammation/Immunology Cancer

Cizutamig (CND-106) is a bispecific T-cell engager targeting BCMA and CD3. Cizutamig exhibits immunostimulatory and anti-tumor activities. Cizutamig can be used in research related to relapsed or refractory multiple myeloma and systemic lupus erythematosus .
loading...
    loading...
Cat. No.: HY-P99798
CAS No.: 2251756-52-0
Synonyms: AMG 420; BI-836909

Target:  

CD3

Research Areas:  

Cancer

Pacanalotamab (AMG 420; BI-836909) is a bispecific T-cell engager (BiTE) targeting to BCMA and CD3E. BCMA refers to B cell maturation antigen, as Pacanalotamab redirecting T cells to BCMA expressing cells on the cell surface. Pacanalotamab conducts T-cell redirected lysis of human multiple myeloma (MM) cell lines .
loading...
    loading...
Cat. No.: HY-P9989
CAS No.: 2408319-25-3
Synonyms: REGN5458

Target:  

CD3 TNF Receptor

Research Areas:  

Cancer

Linvoseltamab (REGN5458) is a bispecific T-cell engager (BiTE) antibody that specifically binds to B cell maturation antigen (BCMA) and CD3 of T cells, thereby directing T cells to multiple myeloma (MM) cells expressing BCMA and activating T cells to kill tumor cells. Linvoseltamab can be used in research of relapsed/refractory multiple myeloma (RRMM) .
loading...
    loading...
Cat. No.: HY-P99430
CAS No.: 2296827-07-9
Synonyms: EM901; CC-93269

Target:  

CD3

Research Areas:  

Inflammation/Immunology Cancer

Alnuctamab (EM901) is a bispecific T-cell engager targeting BCMA and CD3, belonging to an asymmetric two-armed humanized IgG1 antibody. Alnuctamab can simultaneously bind to BCMA expressed on the surface of myeloma cells and CD3 molecules on the surface of T cells, recruiting T cells to kill tumors. Alnuctamab is used for the research of multiple myeloma. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
loading...
    loading...
Cat. No.: HY-P991490

Target:  

CD38 CD3 TNF Receptor

Research Areas:  

Cancer

ISB2001 is a trispecific antibody targeting CD38, CD3 and BCMA. ISB2001 effectively counteracts tumor immune escape mechanisms caused by antigen downregulation, antigen loss, soluble factor competition and other factors. ISB2001 is applicable to relevant research on multiple myeloma and relapsed/refractory multiple myeloma .
loading...
    loading...
Cat. No.: HY-P990070
CAS No.: 2642175-46-8
Synonyms: BION-1301

Target:  

TNF Receptor

Research Areas:  

Inflammation/Immunology Cancer

Zigakibart (BION-1301) is an IgG4-kappa, humanized monoclonal antibody against TNFSF13 (tumor necrosis factor (TNF) superfamily member 13, APRIL, CD256). Zigakibart exhibits anti-inflammatory activity .
loading...
    loading...
Cat. No.: HY-P990095
CAS No.: 2408319-33-3
Synonyms: REGN5459

Target:  

CD3 TNF Receptor

Research Areas:  

Cancer

Vonsetamig (REGN5459) is a human bispecific antibody targeting BCMA and CD3. Vonsetamig triggers T-cell activation, induces plasma cell depletion, and triggers low-level cytokine release. Vonsetamig can be used for the research of relapsed/refractory multiple myeloma .
loading...
    loading...
Cat. No.: HY-P990785
CAS No.: 2490552-52-6
Synonyms: ABBV-383; TNB 383B

Target:  

CD3

Etentamig is a BCMA × CD3 bispecific T-cell engager (BiTE) that can inhibit the activity of B-cell maturation antigen (BCMA) and activate the T-cell surface glycoprotein CD3 complex. Etentamig can be used for research in multiple myeloma, immunoglobulin light chain amyloidosis, and cardiovascular diseases .
loading...
    loading...
Cat. No.: HY-P9980A

Research Areas:  

Cancer

Belantamab (FUT8-KO) is an anti-BCMA (TNFRSF17) monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the ADCC effect of the antibody. Belantamab (FUT8-KO) can be used to synthesize antibody-active molecule conjugate (ADC), Belantamab mafodotin .
loading...
    loading...
Cat. No.: HY-146231A
Purity:  99.88%
Target:  

PROTACs MAP4K

Research Areas:  

Inflammation/Immunology Cancer

SS47 TFA, a PROTAC-based HPK1 degrader, exerts proteasome-mediated HPK1 degradation. The degradation of HPK1 via SS47 also significantly enhances the in vivo antitumor efficacy of BCMA CAR-T cell research. HPK1, an immunosuppressive regulatory kinase, is a promising target for cancer immunotherapies . SS47 (TFA) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
loading...
    loading...
Cat. No.: HY-P1700
CAS No.: 2293841-58-2
Target:  

TNF Receptor

Research Areas:  

Cancer

BCMA72-80 is a HLA-A2-specific B-cell maturation antigen (BCMA) peptide, with great affinity to HLA-A2, used in the research of multiple myeloma or other B-cell maturation antigen expressing tumors .
loading...
    loading...
Cat. No.: HY-P11257
Research Areas:  

Cancer

DOTA-BP1 is a DOTA-modified BP1 (BCMA-targeting peptide). DOTA-BP1 can be radiolabeled with [ 68Ga]Ga to produce a BCMA-targeting PET tracer. DOTA-BP1 can be used in the research of detecting BCMA in multiple myeloma .
loading...
    loading...
Cat. No.: HY-RS14807
Research Areas:  

Others

TNFRSF17 Human Pre-designed siRNA Set A contains three designed siRNAs for TNFRSF17 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

loading...
    loading...
Cat. No.: HY-RS16981
Research Areas:  

Others

Tnfrsf17 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Tnfrsf17 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

loading...
    loading...